280 related articles for article (PubMed ID: 24427545)
1. Myeloid-derived suppressor cells: Cellular missiles to target tumors.
Chandra D; Gravekamp C
Oncoimmunology; 2013 Nov; 2(11):e26967. PubMed ID: 24427545
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice.
Chandra D; Jahangir A; Quispe-Tintaya W; Einstein MH; Gravekamp C
Br J Cancer; 2013 Jun; 108(11):2281-90. PubMed ID: 23640395
[TBL] [Abstract][Full Text] [Related]
3. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
4. 32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect.
Chandra D; Selvanesan BC; Yuan Z; Libutti SK; Koba W; Beck A; Zhu K; Casadevall A; Dadachova E; Gravekamp C
Oncotarget; 2017 Mar; 8(13):20729-20740. PubMed ID: 28186976
[TBL] [Abstract][Full Text] [Related]
5. Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.
Shou D; Wen L; Song Z; Yin J; Sun Q; Gong W
Oncotarget; 2016 Sep; 7(39):64505-64511. PubMed ID: 27542274
[TBL] [Abstract][Full Text] [Related]
6. Nontoxic radioactive Listeria(at) is a highly effective therapy against metastatic pancreatic cancer.
Quispe-Tintaya W; Chandra D; Jahangir A; Harris M; Casadevall A; Dadachova E; Gravekamp C
Proc Natl Acad Sci U S A; 2013 May; 110(21):8668-73. PubMed ID: 23610422
[TBL] [Abstract][Full Text] [Related]
7. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
9. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
10. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
11. Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate.
Meirow Y; Kanterman J; Baniyash M
Front Immunol; 2015; 6():523. PubMed ID: 26528286
[TBL] [Abstract][Full Text] [Related]
12. SOCS3 Suppression Promoted the Recruitment of CD11b
Zhang W; Jiang M; Chen J; Zhang R; Ye Y; Liu P; Yu W; Yu J
Front Immunol; 2018; 9():1699. PubMed ID: 30083161
[TBL] [Abstract][Full Text] [Related]
13. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
14. Targeting Myeloid-Derived Suppressor Cells in Cancer.
Anani W; Shurin MR
Adv Exp Med Biol; 2017; 1036():105-128. PubMed ID: 29275468
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.
Waight JD; Netherby C; Hensen ML; Miller A; Hu Q; Liu S; Bogner PN; Farren MR; Lee KP; Liu K; Abrams SI
J Clin Invest; 2013 Oct; 123(10):4464-78. PubMed ID: 24091328
[TBL] [Abstract][Full Text] [Related]
16. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.
Song J; Lee J; Kim J; Jo S; Kim YJ; Baek JE; Kwon ES; Lee KP; Yang S; Kwon KS; Kim DU; Kang TH; Park YY; Chang S; Cho HJ; Kim SC; Koh SS; Kim S
Oncotarget; 2016 Aug; 7(32):51840-51853. PubMed ID: 27322081
[TBL] [Abstract][Full Text] [Related]
18. Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection.
Tang F; Tie Y; Hong W; Wei Y; Tu C; Wei X
Ann Surg Oncol; 2021 Jul; 28(7):4030-4048. PubMed ID: 33258011
[TBL] [Abstract][Full Text] [Related]
19. Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
Fu SY; Chen FH; Wang CC; Yu CF; Chiang CS; Hong JH
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1547-1558. PubMed ID: 33188861
[TBL] [Abstract][Full Text] [Related]
20. Repression of MUC1 Promotes Expansion and Suppressive Function of Myeloid-Derived Suppressor Cells in Pancreatic and Breast Cancer Murine Models.
Sahraei M; Bose M; Sanders JA; De C; DasRoy L; Nath S; Brouwer CR; Mukherjee P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
